Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

No significant differences were observed in vitamin D, ferritin, iron, or total iron-binding capacity (all p > 0.05) (Table 3).

Source: 2.3. Laboratory Characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Case-control study.

Case-control study

Compares people with an outcome against people without it, examining exposures.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Tissue Advanced Glycation End Product Accumulation and Its Association with Clinical and Laboratory Features, Inflammatory Indices, and Comorbidities in Rheumatoid Arthritis and Ankylosing Spondylitis: A Case: Control Study

Source: Article title.

Participants aged 18 years or older with a confirmed diagnosis of RA or AS were eligible.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Tissue Advanced Glycation End Product Accumulation and Its Association with Clinical and Laboratory Features, Inflammatory Indices, and Comorbidities in Rheumatoid Arthritis and Ankylosing Spondylitis: A Case-Control Study

Case-control study · International Journal of Molecular Sciences · 2026

Original publication title

Tissue Advanced Glycation End Product Accumulation and Its Association with Clinical and Laboratory Features, Inflammatory Indices, and Comorbidities in Rheumatoid Arthritis and Ankylosing Spondylitis: A Case: Control Study

Altuğ Güner; Taner Dandinoğlu

© 2026 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Advanced glycation end products (AGEs) accumulate under chronic inflammation and metabolic stress and may contribute to long-term tissue damage. Skin autofluorescence (SAF) enables non-invasive assessment of tissue AGE accumulation, but data in inflammatory rheumatic diseases remain limited. The present study evaluated AGE-SAF levels in patients with seropositive rheumatoid arthritis (RA) and ankylosing spondylitis (AS) and investigated their associations with disease activity, inflammatory markers, metabolic parameters, and comorbidities. Patients with RA and AS, along with healthy controls, were included. AGE-SAF was measured non-invasively.

Disease activity was assessed using the Disease Activity Score in 28 joints (DAS28) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Between-group comparisons were performed both crudely and after multivariable adjustment for age, sex, and body mass index (BMI). Logistic regression and receiver operating characteristic (ROC) analyses were used to describe the exploratory discriminative performance of AGE-SAF, and propensity score analyses were conducted as sensitivity analyses to address baseline imbalance. In crude comparisons, AGE-SAF levels were higher in RA than in AS and controls, and higher in AS than in controls (p < 0.001).

After adjustment for age, sex, and BMI, AGE-SAF remained significantly elevated in both RA (β = 0.440, 95% CI 0.298 to 0.583, p < 0.001) and AS (β = 0.304, 95% CI 0.183 to 0.425, p < 0.001) compared with controls; however, the difference between RA and AS was no longer statistically significant (β = 0.136, 95% CI −0.051 to 0.323, p = 0.154). Exploratory ROC analyses showed good discrimination for RA versus controls (AUC = 0.851) and moderate discrimination for AS versus controls (AUC = 0.695), whereas discrimination between RA and AS was limited (AUC = 0.670).

In overlap-weighted sensitivity analysis, the RA-AS difference remained non-significant (β = 0.161, p = 0.293). AGE-SAF is elevated in inflammatory rheumatic diseases compared with healthy controls, and this elevation persists after adjustment for age, sex, and BMI. Although crude AGE-SAF values were higher in RA than in AS, this difference attenuated after confounder adjustment, indicating that a substantial part of the between-disease difference is attributable to demographic and treatment-related imbalance. AGE-SAF may therefore reflect cumulative disease-related and vascular: metabolic burden across both diseases rather than a disease-specific phenomenon.

Authors’ abstract

Advanced glycation end products (AGEs) accumulate under chronic inflammation and metabolic stress and may contribute to long-term tissue damage. Skin autofluorescence (SAF) enables non-invasive assessment of tissue AGE accumulation, but data in inflammatory rheumatic diseases remain limited. The present study evaluated AGE-SAF levels in patients with seropositive rheumatoid arthritis (RA) and ankylosing spondylitis (AS) and investigated their associations with disease activity, inflammatory markers, metabolic parameters, and comorbidities. Patients with RA and AS, along with healthy controls, were included. AGE-SAF was measured non-invasively.

Disease activity was assessed using the Disease Activity Score in 28 joints (DAS28) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Between-group comparisons were performed both crudely and after multivariable adjustment for age, sex, and body mass index (BMI). Logistic regression and receiver operating characteristic (ROC) analyses were used to describe the exploratory discriminative performance of AGE-SAF, and propensity score analyses were conducted as sensitivity analyses to address baseline imbalance. In crude comparisons, AGE-SAF levels were higher in RA than in AS and controls, and higher in AS than in controls (p < 0.001).

After adjustment for age, sex, and BMI, AGE-SAF remained significantly elevated in both RA (β = 0.440, 95% CI 0.298 to 0.583, p < 0.001) and AS (β = 0.304, 95% CI 0.183 to 0.425, p < 0.001) compared with controls; however, the difference between RA and AS was no longer statistically significant (β = 0.136, 95% CI −0.051 to 0.323, p = 0.154). Exploratory ROC analyses showed good discrimination for RA versus controls (AUC = 0.851) and moderate discrimination for AS versus controls (AUC = 0.695), whereas discrimination between RA and AS was limited (AUC = 0.670).

In overlap-weighted sensitivity analysis, the RA-AS difference remained non-significant (β = 0.161, p = 0.293). AGE-SAF is elevated in inflammatory rheumatic diseases compared with healthy controls, and this elevation persists after adjustment for age, sex, and BMI. Although crude AGE-SAF values were higher in RA than in AS, this difference attenuated after confounder adjustment, indicating that a substantial part of the between-disease difference is attributable to demographic and treatment-related imbalance. AGE-SAF may therefore reflect cumulative disease-related and vascular: metabolic burden across both diseases rather than a disease-specific phenomenon.

Publication and source details

Original title: Tissue Advanced Glycation End Product Accumulation and Its Association with Clinical and Laboratory Features, Inflammatory Indices, and Comorbidities in Rheumatoid Arthritis and Ankylosing Spondylitis: A Case: Control Study

Altuğ Güner; Taner Dandinoğlu

International Journal of Molecular Sciences · 2026

* Correspondence: guner_88_8@hotmail.com© 2026 by the authors.2026https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.This research received no external funding.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T23:17:59.855103+00:00

DOI: 10.3390/ijms27094027 · PMC13164295